In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|March 10, 2020
INTERPHEX Rescheduled Due to COVID-19
Author(s)BioPharm International Editors
New dates for the postponed event are still being determined.
Advertisement
Reed Exhibitions announced on March 11, 2020 that it was rescheduling its pharmaceutical industry event, INTERPHEX- originally scheduled to take place April 28–30 at the Javits Center in New York City-to July 15–17 at the same location because of concerns surrounding COVID-19.
“We know how important INTERPHEX is to our customers’ business and it is our top priority to provide the forum for INTERPHEX and Chemspec USA to allow business to continue,” said Randy Field, group vice president, Reed Exhibitions, in the press release. “The INTERPHEX community is uniquely equipped to support authorities and have a positive impact on addressing the COVID-19 virus. Therefore, we’ve made the decision to postpone INTERPHEX 2020 to July 15–17, 2020. We believe this is the right decision for our customers and the industry in general, which is a vital part of getting the pharmaceutical supply chain back on track post-outbreak.”
“We are working with our partners to find solutions to logistical and operational issues that may arise," Field added. "We are here to help, but ask for your patience as we ensure all of our customers are taken care of. With that in mind, please make sure to change hotels, flights, and any other arrangements. Information regarding airline change fee waivers is available on our website.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5